Cost-Effectiveness Analysis of the??Addition of Rituximab to CHOP??in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma

Clinical Drug Investigation ◽

10.2165/00044011-200828010-00007 ◽

2008 ◽

Vol 28 (1) ◽

pp. 55-65 ◽

Author(s):

Felicetto Ferrara ◽

Roberto Ravasio

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Abstract 75: Cost-effectiveness Analysis of CHOP and R-CHOP Treatment of Diffuse Large B-cell Lymphoma in Malawi

10.1158/1538-7755.asgcr21-75 ◽

2021 ◽

Author(s):

Matthew Painschab ◽

Racquel Kohler ◽

Stephen Kimani ◽

Stephanie Wheeler ◽

Satish Gopal

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan

Transplantation and Cellular Therapy ◽

10.1016/j.jtct.2021.03.005 ◽

2021 ◽

Author(s):

Shiho Wakase ◽

Takanori Teshima ◽

Jie Zhang ◽

Qiufei Ma ◽

Taizo Fujita ◽

...

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Cost Effectiveness Analysis ◽

Adult Patients ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis

The Lancet Global Health ◽

10.1016/s2214-109x(21)00261-8 ◽

2021 ◽

Author(s):

Matthew S Painschab ◽

Racquel Kohler ◽

Stephen Kimani ◽

Wilberforce Mhango ◽

Bongani Kaimila ◽

...

Keyword(s):

Cost Effectiveness ◽

Supportive Care ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Best Supportive Care ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

PCN92 COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH RITUXIMAB AND BEVACIZUMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Value in Health ◽

10.1016/j.jval.2020.04.1592 ◽

2020 ◽

Vol 23 ◽

pp. S40

Author(s):

C. Balmaceda ◽

T. Abbott ◽

M.A. Espinoza

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma

Value in Health ◽

10.1111/j.1524-4733.2005.00037.x ◽

2005 ◽

Vol 8 (4) ◽

pp. 462-470 ◽

Author(s):

Jennie H. Best ◽

John Hornberger ◽

Stephen J. Proctor ◽

Louis F. Omnes ◽

Fred Jost

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Rituximab in Treatmenting Diffuse Large B-Cell Lymphoma in China

Value in Health ◽

10.1016/j.jval.2015.09.1320 ◽

2015 ◽

Vol 18 (7) ◽

pp. A483-A484

Author(s):

L Qian

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Clinical Therapeutics ◽

10.1016/j.clinthera.2021.06.011 ◽

2021 ◽

Author(s):

Cynthia Z. Qi ◽

Vamsi Bollu ◽

Hongbo Yang ◽

Anand Dalal ◽

Su Zhang ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

The United States ◽

Cost Effectiveness Analysis ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Download Full-text

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

The Lancet Oncology ◽

10.1016/s1470-2045(08)70078-0 ◽

2008 ◽

Vol 9 (5) ◽

pp. 435-444 ◽

Author(s):

Michael Pfreundschuh ◽

Anthony D Ho ◽

Eva Cavallin-Stahl ◽

Max Wolf ◽

Ruth Pettengell ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Prognostic Significance ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Trial Group ◽

Large B Cell Lymphoma ◽

Tumour Bulk ◽

Download Full-text

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

The Lancet Oncology ◽

10.1016/s1470-2045(11)70235-2 ◽

2011 ◽

Vol 12 (11) ◽

pp. 1013-1022 ◽

Author(s):

Michael Pfreundschuh ◽

Evelyn Kuhnt ◽

Lorenz Trümper ◽

Anders Österborg ◽

Marek Trneny ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Randomised Study ◽

International Trial ◽

Large B Cell Lymphoma ◽

Download Full-text

Faculty Opinions recommendation of CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14204.471770 ◽

2006 ◽

Author(s):

Louis Diehl

Keyword(s):

Randomised Controlled Trial ◽

B Cell ◽

Cell Lymphoma ◽

Controlled Trial ◽

Young Patients ◽

B Cell Lymphoma ◽

Good Prognosis ◽

Large B Cell Lymphoma ◽

Randomised Controlled ◽

Download Full-text